Core Viewpoint - The company has successfully obtained patents for its core product CBT-009 in both Japan and Europe, which are crucial for its business strategy in the ophthalmic treatment market [1]. Patent Details - A patent was granted by the Japan Patent Office on September 25, 2025, under patent number 7749020, which covers various ophthalmic topical compositions, including a specific formulation of atropine, medium-chain triglyceride liquid carriers, and selected perfluorinated hydrocarbons, aimed at delaying the progression of myopia [1]. - The European Patent Office granted a patent on November 26, 2025, under patent number 4225284, which also includes compositions for treating myopia and other eye diseases, utilizing atropine and perfluorinated hydrocarbons as liquid carriers [1].
拨康视云-B(02592.HK)附属获日本及欧洲两项专利 用于核心产品CBT-009延缓近视及眼部疾病治疗